Currently, these phenotypes are most well studied in melanoma and lung cancer cell lines reported to develop acquired resistance to targeted therapy which appears to be characterised by inducible and reversible enrichment of interferon (IFN) pathway signalling [6, 7, 13], cell cycle inhibition [16, 18, 19] and transcriptional repression of a subset of genes due to increased repressive chromatin modifications such as trimethylation of histone 3 lysine 9 (H3K9me3) [14, 15]. This evidence concerns the gene IFNA1 and lung carcinoma.